Notice: This company has been marked as potentially delisted and may not be actively trading. GTX (GTXI) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrends GTXI vs. SABS, CRIS, BOLT, MTEM, AMGN, VRTX, GILD, REGN, ALNY, and BIIBShould you be buying GTX stock or one of its competitors? The main competitors of GTX include SAB Biotherapeutics (SABS), Curis (CRIS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Biogen (BIIB). These companies are all part of the "biotechnology" industry. GTX vs. SAB Biotherapeutics Curis Bolt Biotherapeutics Molecular Templates Amgen Vertex Pharmaceuticals Gilead Sciences Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen GTX (NASDAQ:GTXI) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends. Which has preferable earnings and valuation, GTXI or SABS? GTX has higher earnings, but lower revenue than SAB Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGTXN/AN/A-$38.42M-$1.65-0.32SAB Biotherapeutics$2.24M19.16-$42.19MN/AN/A Do analysts rate GTXI or SABS? SAB Biotherapeutics has a consensus target price of $12.40, indicating a potential upside of 166.67%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe SAB Biotherapeutics is more favorable than GTX.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GTX 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00SAB Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, GTXI or SABS? GTX has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Does the MarketBeat Community prefer GTXI or SABS? GTX received 288 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. However, 81.82% of users gave SAB Biotherapeutics an outperform vote while only 73.60% of users gave GTX an outperform vote. CompanyUnderperformOutperformGTXOutperform Votes31573.60% Underperform Votes11326.40% SAB BiotherapeuticsOutperform Votes2781.82% Underperform Votes618.18% Do insiders & institutionals have more ownership in GTXI or SABS? 9.5% of GTX shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 40.9% of GTX shares are owned by company insiders. Comparatively, 26.5% of SAB Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is GTXI or SABS more profitable? GTX has a net margin of 0.00% compared to SAB Biotherapeutics' net margin of -1,450.14%. SAB Biotherapeutics' return on equity of -94.37% beat GTX's return on equity.Company Net Margins Return on Equity Return on Assets GTXN/A -104.19% -86.42% SAB Biotherapeutics -1,450.14%-94.37%-67.26% Does the media prefer GTXI or SABS? In the previous week, GTX's average media sentiment score of 0.00 equaled SAB Biotherapeutics'average media sentiment score. Company Overall Sentiment GTX Neutral SAB Biotherapeutics Neutral SummarySAB Biotherapeutics beats GTX on 7 of the 13 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get GTX News Delivered to You Automatically Sign up to receive the latest news and ratings for GTXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GTXI vs. The Competition Export to ExcelMetricGTXPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.67M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E Ratio-0.3210.5990.0517.18Price / SalesN/A196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book0.485.094.784.78Net Income-$38.42M$151.83M$120.31M$225.60M GTX Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GTXIGTXN/A$0.53flatN/AN/A$12.67MN/A-0.3221SABSSAB Biotherapeutics2.4192 of 5 stars$4.01-1.7%$12.40+209.2%+532.7%$37.01M$2.24M0.00140Gap UpCRISCuris2.5226 of 5 stars$3.51-1.7%$23.00+555.3%-75.7%$29.72M$10.26M-0.4849BOLTBolt Biotherapeutics2.4659 of 5 stars$0.52-1.9%$3.50+575.7%-49.8%$19.82M$7.88M-0.31100High Trading VolumeMTEMMolecular Templates3.1935 of 5 stars$0.37-6.9%N/A-95.7%$2.45M$57.31M-0.1562News CoverageGap DownAMGNAmgen4.4625 of 5 stars$266.50-1.5%$319.68+20.0%-5.7%$143.25B$32.53B34.8626,700Analyst DowngradeGap UpVRTXVertex Pharmaceuticals4.7494 of 5 stars$468.09+0.9%$505.73+8.0%-0.8%$120.55B$9.87B-233.035,400Analyst ForecastAnalyst RevisionNews CoverageGILDGilead Sciences4.4195 of 5 stars$92.05+0.2%$96.43+4.8%+17.3%$114.72B$27.12B1,020.6718,000Insider TradeREGNRegeneron Pharmaceuticals4.6604 of 5 stars$724.65-0.9%$1,099.90+51.8%-16.6%$79.63B$13.12B18.1013,450Analyst ForecastALNYAlnylam Pharmaceuticals4.3497 of 5 stars$244.28-0.5%$298.09+22.0%+35.5%$31.51B$1.83B-93.682,100Analyst UpgradeBIIBBiogen4.6279 of 5 stars$150.48+0.3%$245.32+63.0%-42.3%$21.93B$9.61B13.697,570Analyst Downgrade Related Companies and Tools Related Companies SAB Biotherapeutics Competitors Curis Competitors Bolt Biotherapeutics Competitors Molecular Templates Competitors Amgen Competitors Vertex Pharmaceuticals Competitors Gilead Sciences Competitors Regeneron Pharmaceuticals Competitors Alnylam Pharmaceuticals Competitors Biogen Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GTXI) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GTx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GTX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
